Device Trial Radar · NCT05161806
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Last checked: Nov 19, 2026Latest source record: Nov 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 11, 2022
Primary completion
May 4, 2022
Study completion May 4, 2022
Sponsor
- Lead sponsor
- SandozNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL)Drug
SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
Prefilled Syringe (PFS)Device
Prefilled Syringe (PFS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Ocular Treatment Emergent Adverse EventsTime frame: throughout the study, approximately 31 days
- Number of Participants With Non-ocular Treatment Emergent Adverse EventsTime frame: throughout the study, approximately 31 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Sandoz Investigational Site
Marietta, Georgia
Sandoz Investigational Site
Oak Forest, Illinois
Sandoz Investigational Site
Liverpool, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.